A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
Trial ID or NCT#
NCT00761696
Status
NOT RECRUITING
Purpose
The primary objectives of the study are: * To determine the safety and the maximum tolerated dose (MTD) of IPI-926 * To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) * To recommend a dose and schedule of IPI-926 for subsequent studies
Official Title
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
Investigator(s)
Anthony E Oro
Dermatologist,
Hair loss specialist,
Dermatologic oncologist,
Cutaneous oncology specialist,
Skin stem cell specialist
Eugene and Gloria Bauer Professor
Anne Lynn S Chang
Dermatologist,
General dermatologist,
Dermatologic oncologist,
Cutaneous oncology specialist
Professor of Dermatology
Contact us to find out if this trial is right for you.
Contact
Cancer Clinical Trials Office
650-498-7061
View on ClinicalTrials.gov
